tetano
Editor, Senior Moderator
Infect Chemother
. 2022 Sep 7.
doi: 10.3947/ic.2022.0103. Online ahead of print.
Use of the Monoclonal Antibody Regdanvimab to Treat Patients Hospitalized with COVID-19: Real-World Data during the Delta Variant Predominance
Yee Gyung Kwak[SUP] 1 [/SUP], Je Eun Song[SUP] 1 [/SUP], Jieun Kang[SUP] 1 [/SUP], Jiyeon Kang[SUP] 1 [/SUP], Hyung Koo Kang[SUP] 1 [/SUP], Hyeon-Kyoung Koo[SUP] 1 [/SUP], Hye Kyeong Park[SUP] 1 [/SUP], Sang Bong Choi[SUP] 2 [/SUP], Hyuk Pyo Lee[SUP] 2 [/SUP], Myung Jin Lee[SUP] 2 [/SUP], Baek-Nam Kim[SUP] 3 [/SUP]
Affiliations
Abstract
Regdanvimab is the only monoclonal antibody available in Korea that targets severe acute respiratory syndrome coronavirus 2. We retrospectively evaluated the clinical characteristics of 374 adults hospitalized with coronavirus disease 2019 (COVID-19) who were treated with regdanvimab from September through December 2021. In total, 322 (86.1%) patients exhibited risk factors for disease progression. Most patients (91.4%) improved without additional treatment. No patient died or was transferred to intensive care. This study shows that regdanvimab prevented disease progression in high-risk patients with mild to moderate COVID-19 infections during Delta variant predominance.
Keywords: COVID-19; Delta variant; Regdanvimab.
. 2022 Sep 7.
doi: 10.3947/ic.2022.0103. Online ahead of print.
Use of the Monoclonal Antibody Regdanvimab to Treat Patients Hospitalized with COVID-19: Real-World Data during the Delta Variant Predominance
Yee Gyung Kwak[SUP] 1 [/SUP], Je Eun Song[SUP] 1 [/SUP], Jieun Kang[SUP] 1 [/SUP], Jiyeon Kang[SUP] 1 [/SUP], Hyung Koo Kang[SUP] 1 [/SUP], Hyeon-Kyoung Koo[SUP] 1 [/SUP], Hye Kyeong Park[SUP] 1 [/SUP], Sang Bong Choi[SUP] 2 [/SUP], Hyuk Pyo Lee[SUP] 2 [/SUP], Myung Jin Lee[SUP] 2 [/SUP], Baek-Nam Kim[SUP] 3 [/SUP]
Affiliations
- PMID: 36226346
- DOI: 10.3947/ic.2022.0103
Abstract
Regdanvimab is the only monoclonal antibody available in Korea that targets severe acute respiratory syndrome coronavirus 2. We retrospectively evaluated the clinical characteristics of 374 adults hospitalized with coronavirus disease 2019 (COVID-19) who were treated with regdanvimab from September through December 2021. In total, 322 (86.1%) patients exhibited risk factors for disease progression. Most patients (91.4%) improved without additional treatment. No patient died or was transferred to intensive care. This study shows that regdanvimab prevented disease progression in high-risk patients with mild to moderate COVID-19 infections during Delta variant predominance.
Keywords: COVID-19; Delta variant; Regdanvimab.